PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877442
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1877442
The Molecular Glue Degradation Agent Market size was valued at US$ 402 Million in 2024, expanding at a CAGR 8.6% from 2025 to 2032.
The Molecular Glue Degradation Agent Market is an emerging segment of targeted protein degradation (TPD) therapies that use molecular glues-small molecules that induce proximity between a target protein and an E3 ubiquitin ligase, resulting in selective protein degradation. The Molecular Glue Degradation Agent Market is expanding rapidly, driven by the growing demand for therapies capable of degrading previously "undruggable" proteins, particularly in oncology and rare diseases. A major market trend is the rapid adoption of AI-enabled platforms and structure-based design tools, which accelerate the discovery of novel molecular glue degraders. However, a significant challenge to faster commercial progress is a lack of regulatory clarity, as well as the difficulty of predicting target selectivity and off-target effects in early development. Despite this, there is a significant opportunity to expand molecular glue applications beyond cancer to include neurodegenerative, inflammatory, and metabolic disorders, where targeted protein degradation could lead to first-in-class therapeutic breakthroughs.
Molecular Glue Degradation Agent Market- Market Dynamics
Growing Demand for Sustainable Manufacturing Propels Market Growth
The rising demand for sustainable manufacturing is a significant growth driver in the Molecular Glue Degradation Agent market, as pharmaceutical companies prioritize environmentally responsible drug development. Molecular glues contribute to sustainability goals by allowing for targeted protein degradation using small, efficient molecules that require fewer raw materials, have simpler synthesis steps, and produce less chemical waste than traditional approaches. As global pressure grows to reduce pharmaceutical production's environmental footprint, manufacturers are accelerating the use of greener chemistry and energy-efficient development platforms. Strategic industry collaborations help to reinforce this trend. For instance, in May 2024, Takeda Pharmaceuticals signed a licensing agreement with Degron Therapeutics worth up to USD 1.2 billion to develop scalable molecular glue degraders, reflecting the market's shift toward more sustainable and resource-efficient therapeutic solutions. This sustainable trend is expected to drive market growth in the coming years.
The worldwide market is segmented on the basis of Type, Delivery Method, End User, Application, and Region.
Based End-User segmentation, the pharmaceutical company's segment is one of the most important categories in the Global Molecular Glue Degradation Agent Market because they drive clinical development and commercialization of new targeted therapies. Molecular glues, such as PROTACs and LYTACs, are increasingly being studied for their ability to selectively degrade disease-causing proteins, making them ideal for novel drug pipelines. For instance, In December 2024, Monte Rosa Therapeutics reported that the dose-escalation phase of its Phase I/II trial of MRT-2359 demonstrated a favorable safety profile and effective GSPT1 degradation using a 21-day-on, 7-day-off dosing regimen in heavily pretreated solid tumor patients. Further clinical data, including biomarker and activity insights, are expected in Q1 2025, highlighting ongoing progress in targeted protein degradation in the pharmaceutical and biotechnology industries.
Based on Type segment, The Proteolytic Targeting Chimeras (PROTAC-like) segment is an important component in the Molecular Glue Degradation Agent Market because it allows for the selective recruitment of E3 ubiquitin ligases to degrade pathogenic proteins, providing a powerful solution for previously "undruggable" targets. Its significance is underscored by robust industry activity, such as Monte Rosa Therapeutics' advances in molecular glue degraders. In April 2025, the company presented preclinical data demonstrating that its CDK2-directed degrader MRT-51443 improved tumor regression in HR-positive/HER2-negative breast cancer models when combined with existing therapies. Monte Rosa's 2025 pipeline update also highlighted upcoming IND submissions, including MRT-8102 for NEK7 degradation and the continued development of solid-tumor candidate MRT-2359. Monte Rosa's major partnership with Novartis in late 2024, which included a $150 million upfront payment and potential milestones exceeding $2 billion for its VAV1-targeted glue degraders, underscores the segment's commercial relevance. These developments collectively highlight the PROTAC-like segment as a high-value growth engine in the molecular glue degradation ecosystem.
Molecular Glue Degradation Agent Market- Geographical Insights
North America's market is distinguished by significant investments in biotechnology and pharmaceutical research, which are supported by a robust infrastructure and a concentration of leading research institutions and companies. Meanwhile, the Middle East and Africa offer a diverse market landscape, with growth opportunities driven by improved healthcare systems and investments in life sciences. Finally, Latin America is gradually expanding, with increased interest in biopharmaceutical development and collaborations creating an enabling environment for biotechnology advancement. The geographical segmentation highlights varying degrees of maturation, investment, and regulatory environments, which have a significant impact on global market dynamics for molecular glue degradation agents.
United States Molecular Glue Degradation Agent Market- Country Insights
The United States is the most important country in the North American Molecular Glue Degradation Agent Market due to its robust biotech ecosystem, advanced research infrastructure, and rapid adoption of next-generation targeted protein degradation technologies. The country is home to leading pharmaceutical innovators, top academic research institutions, and a dense network of clinical trial sites, allowing for faster translation of molecular glue concepts into clinical-stage therapeutics. Furthermore, the United States benefits from supportive FDA pathways for breakthrough therapies and robust venture capital investment, both of which accelerate market expansion. This leadership is evident in developments such as AbbVie's January 2025 collaboration with Neomorph, in which the biotech received up to USD 1.64 billion to advance molecular glue degraders in oncology and immunology-demonstrating how U.S.-led partnerships and funding commitments are shaping the global trajectory of molecular glue technologies.
The Molecular Glue Degradation Agent market is highly competitive, driven by innovation in targeted protein degradation and strategic collaborations. Arvinas, a pioneer in PROTAC and molecular glue technologies, has advanced multiple candidates to clinical trials in oncology and other areas. Kymera Therapeutics is well-known for its proprietary E3 ligase-targeting platforms and lucrative collaborations with Gilead and other pharmaceutical companies to develop novel molecular glues. C4 Therapeutics also uses its integrated BiDAC and MonoDAC platforms to accelerate the discovery and clinical development of molecular glue degraders. These companies, along with other innovators such as AbbVie and Genentech, are shaping the competitive landscape through technological leadership, pipeline advancement, and strategic alliances, putting them at the forefront of this rapidly changing market.
In March 2025, Magnet Biomedicine has formed a collaboration and licensing agreement with Eli Lilly to identify, develop, and market oncology-focused molecular glue therapies.
In January 2025, AbbVie and Neomorph, Inc. announced a collaboration and licensing agreement to develop novel molecular glue degraders for oncology and immunology.